
FDA approves Click’s digital therapeutic for episodic migraine
More than 37 million adults in the US are affected by migraine The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132 as the first prescription digital therapeutic for the prevention of episodic migraine. CT-132, which can now be …